Hong Kong Biotech Stock News

It's not a stretch to say that MTR Corporation Limited's ( HKG:66 ) price-to-earnings (or "P/E") ratio of 12.1x right...

Operating results put Cathay Pacific Airways (SEHK:293) in focus Cathay Pacific Airways (SEHK:293) has attracted fresh attention after reporting December 2025 and full year traffic figures, with double digit year on year growth in both passenger volumes and cargo tonnage. See our latest analysis for Cathay Pacific Airways. The HK$12.58 share price has been supported by an 11.72% 90 day share price return and a 27.65% 1 year total shareholder return, suggesting momentum has been building...

Why East Buy Holding (SEHK:1797) is in focus ahead of earnings East Buy Holding (SEHK:1797) is drawing attention as it heads into its 28 January 2026 earnings release, with investors closely watching revenue growth, margin trends and management guidance. See our latest analysis for East Buy Holding. At a share price of HK$23.08, East Buy Holding has recently seen a 27.73% 1 month share price return and a 44.97% 1 year total shareholder return. However, the 3 year total shareholder return of a...

In recent research released before 26 January 2026, Citi and UOB Kay Hian highlighted that China Overseas Land & Investment faces expected profit margin pressure, deeper write-offs, and weaker 2025 earnings across China’s stressed real-estate sector. At the same time, both brokers continued to single out China Overseas Land & Investment as one of the relatively stronger developers within a sector undergoing restructuring and impairment-driven reset. We’ll now examine how this combination of...

CStone Pharmaceuticals (SEHK:2616) has moved to refresh its governance and incentive structure, pairing a large equity award package for director and staff with board changes that bring new financial expertise and committee leadership. See our latest analysis for CStone Pharmaceuticals. These governance moves come as CStone’s share price trades at HK$5.43, with a 1-year total shareholder return of 132.05% contrasting with a 5-year total shareholder return of 52.03% and a softer 90-day share...

In January 2026, Shanghai Fudan Microelectronics Group issued unaudited guidance for 2025, expecting revenue of about RMB 3,930,000,000 to RMB 4,030,000,000, but projecting net profit attributable to shareholders to fall to roughly RMB 190,000,000 to RMB 283,000,000 and core net profit after non-recurring items to RMB 125,000,000 to RMB 185,000,000. The company links this profit compression to inventory impairment after earlier stockpiling, higher research and development expenses from...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...

Crystal International Group recently announced plans to acquire a large industrial land parcel in Egypt for about US$30.40 million to build new production plants and supporting facilities, subject to local government approval. This move signals a push to broaden its manufacturing footprint, reduce exposure to concentrated geopolitical and trade-policy risks, and offer global customers more flexible sourcing options. We will now examine how this planned Egypt expansion, aimed at diversifying...

As global markets navigate a period of volatility and geopolitical uncertainty, the Asian market continues to present intriguing opportunities for investors, particularly in the realm of growth companies with high insider ownership. In this environment, stocks that demonstrate robust earnings growth and strong insider commitment can offer a compelling mix of potential stability and upside, making them noteworthy considerations for those looking to understand current trends in Asia's evolving...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

OSL Group has issued earnings guidance indicating a net loss from continuing operations of HK$370 million to HK$430 million for FY2025, compared with a profit of about HK$55 million in FY2024, driven by higher expansion costs, fair value losses on digital assets and one-off professional fees. Despite the loss guidance, the group forecasts IFRS income from its digital assets and blockchain platform business to rise to HK$450 million–HK$530 million and adjusted non-IFRS income to HK$490...

Key Insights Aluminum Corporation of China's significant retail investors ownership suggests that the key decisions are...

Key Insights The projected fair value for Beijing Enterprises Holdings is HK$45.73 based on Dividend Discount Model...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

There wouldn't be many who think InnoCare Pharma Limited's ( HKG:9969 ) price-to-sales (or "P/S") ratio of 12.5x is...

We wouldn't blame Acme International Holdings Limited ( HKG:1870 ) shareholders if they were a little worried about the...

It might be of some concern to shareholders to see the MGM China Holdings Limited ( HKG:2282 ) share price down 17% in...

Key Insights Minsheng Education Group's significant insider ownership suggests inherent interests in company's...

Those holding Modern Chinese Medicine Group Co., Ltd. ( HKG:1643 ) shares would be relieved that the share price has...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

With a price-to-earnings (or "P/E") ratio of 19x Galaxy Entertainment Group Limited ( HKG:27 ) may be sending very...

Genscript Biotech (SEHK:1548) is back in focus after its associate Legend Biotech reported approximately US$555 million in Q4 2025 net trade sales of multiple myeloma cell therapy CARVYKTI®, underscoring meaningful commercial traction. See our latest analysis for Genscript Biotech. Legend Biotech’s CARVYKTI® sales update has arrived after a mixed year for Genscript Biotech, with the share price at HK$13.3, a year to date share price return of 3.99%, a 1 year total shareholder return of 26.19%...

Production update and why it matters for CGN Mining CGN Mining (SEHK:1164) has released unaudited natural uranium production figures, reporting 702.5 tU for the fourth quarter of 2025 and 2,699.0 tU for the full year. This provides investors with fresh insight into recent operating performance. See our latest analysis for CGN Mining. The production update lands after a strong run in the shares. The latest HK$4.3 price comes alongside a 32.72% year to date share price return and a very large 5...